International Lung Cancer Summit

📢 Save the date! 13th November 2026 📆 Join us for ILCS26, the 8th edition of our global hybrid conference. Global experts will join our hosts @peters_solange & @Alfdoc2 to discuss emerging biomarkers, new drug classes such as ADCs, T-Cell Engagers as well as combination therapies with IO and TKIs for people with lung cancer. Revisit last year's gallery to get a glimpse of what is to come ⬇️ lungsummit.org/pics/

At our Year in Review roundtable, @MartinReck2 and @charlesrudin discussed whether consolidation therapy with DLL3 bispecific T-cell engagers could extend into limited stage NSCLC, alongside a potential role in the perioperative management of very early SCLC. Both emphasized that such small patient populations still deserve careful study when the goal is improving long term cure rates. Could these indications soon be ready to revisit? Watch the full discussion with @peters_solange ⬇️ lungsummit.org/sclc/

What is the role of tissue biopsy at progression in EGFR+ NSCLC, when liquid biopsy may be an alternative? At ILCS 2025, @peters_solange asked @TommyJohn00. His view: tissue is essential when accessible. More tissue biopsies have revealed more small cell transformation than expected, often without phenotypic clues, and liquid biopsy will miss it. Watch the full discussion to learn how rebiopsy practice is evolving after progression ⬇️ lungsummit.org/targeted-thera…

Can targeted rechallenge restore response to immunotherapy in heavily pre-treated lung cancer? At ILCS 2025, @MdCurioni shared two strategies. SAKK 17/18 combined PD-(L)1 inhibition with a steroid free gemcitabine, reaching ORR 31% and DCR 53%. RECLAIM added radiotherapy at up to four sites to dual checkpoint blockade after anti-PD-1 failure, with ORR 29%. Watch the full discussion to learn more about strategies in 2L and beyond ⬇️ lungsummit.org/metastatic-nsc…

Is a triplet of chemotherapy, immunotherapy, and KRAS inhibitors an overtreatment or the future for KRAS mutated NSCLC? @MartinReck2 addressed this question from @g_mountzios end of 2025 during our roundtable session. We may see further data this year or next on how to approach patients with resistance co-mutations such as STK11 or KEAP1, and whether further intensification will be required or chemo-free options will be suitable. Watch the discussion with @peters_solange and @charlesrudin ⬇️ lungsummit.org/all-sessions/

How far can we extend targeted therapy into earlier stages of lung cancer? At ILCS 2025, @hausruck1 raised this key question, sparking discussion with @TommyJohn00 on whether every actionable target truly needs its own registrational trial. Given the data we see from NeoADAURA, ALINA and NAUTIKA1, class effects might challenge the one-trial-per-target paradigm for rare targets. Watch the exchange ⬇️ lungsummit.org/targeted-thera…

What are our options to manage adverse events, especially oedema, associated with MET inhibition? During our Year in Review roundtable, @peters_solange & @MartinReck2 addressed the "troublesome" nature of MET toxicities, which may lead to ICU admissions. @MartinReck2 noted these events often resist diuretics or steroids, leaving dose modification as the primary strategy. Watch the full discussion with @charlesrudin ⬇️ lungsummit.org/targeted-thera…

How will the therapeutic landscape of thoracic oncology shift by the end of 2026? Join our chairs @peters_solange & @Alfdoc2 for the International Lung Cancer Summit 2026. Whether onsite in Lausanne or live online, we’ll synthesize a year of clinical breakthroughs to define the next standards in care. 🗓️ Friday, Nov 13th, 2026 📍 Lausanne, Switzerland & Live Online 🚀 Registration opens 1st June Save the date and mark your calendars! ⬇️ #ILCS" target="_blank" rel="nofollow noopener">lungsummit.org/#ILCS

How should we distinguish ADCs versus TKIs when targeting HER2-mutant NSCLC? At ILCS 2025, @stephanieplsaw explained that while TKIs bind the intracellular domain to block phosphorylation, ADCs target the extracellular domain to trigger endocytosis and direct "cancer kill". With ~90% of mutations occurring in exon 20, understanding these distinct pathways might be critical for sequencing approaches with these compounds. Watch here ⬇️ lungsummit.org/targeted-thera…

Is re-biopsy necessary when managing oligoprogression in EGFR-mutant NSCLC? During our Year in Review roundtable, @MartinReck2 and @peters_solange asked about the definition of oligoprogression itself. While re-biopsy helps track molecular evolution, @MartinReck2 noted that local radiotherapy without re-biopsy and testing is often appropriate in this setting. Watch the full discussion with @charlesrudin ⬇️ lungsummit.org/all-sessions/

After decades of incremental progress, are we finally entering a new era of hope for SCLC? At ILCS 2025, @RManochakian summarized the shifting standards in limited and extensive stage disease. While consolidation immunotherapy is now standard after CRT, the arrival of TCEs like tarlatamab in 2L and emerging B7-H3-directed ADCs suggest the landscape is finally moving beyond simple platinum backbones. Watch his full summary ⬇️ lungsummit.org/sclc/

How are we treating PD-L1 negative NSCLC today, and are we still only scratching the surface of its biology? In our conversation with @MdCurioni, we looked at how real-world data from the HFR register align with clinical trial evidence. She highlighted the value of rapid biomarker testing in this subgroup, where ECOG status and comorbidities often guide the choice between the various 1L combination strategies now available. Watch the full interview here ⬇️ lungsummit.org/all-sessions/

Discussion about immunotherapy in early stage NSCLC at the US Focus Meeting on lung cancer led by Drs. Tina Cascone @ryangentzler @BalazsHalmosMD @HyeinJeon_MD - desire to escalate for non pCR but how?

Fantastic and thought provoking talks on KRAS, HER2, BRAF, and MET at the IS Focus Meeting on Lung Cancer from Drs. @MLJohnsonMD2 Mark Kris and @LealTiciana. KRAS G12C particularly dynamic ahead of some very important read outs coming in the very near future.

Is there room for neoadjuvant intensification strategies using ADCs in early-stage NSCLC? At ILCS 2025, @NReguart discussed the NEOCOAST-2 platform led by Tina Cascone, highlighting Arm 4 (durvalumab + Dato-DXd + platinum). This combination achieved a pCR of 35% and an MPR of 66%, showing promising activity even in PD-L1 negative patients (~31% pCR). However, we will have to carefully balance these high response rates and ctDNA clearance against potential toxicity. Watch her full talk ⬇️ lungsummit.org/adcs/

Is the concept of oligo-residual radiation in EGFR+ advanced NSCLC moving from anecdote to evidence? At our Year in Review, @MartinReck2 and @peters_solange unpacked the NORTHSTAR trial and highlighted an important nuance: it was designed to delay progression, not to cure. What stood out just as much was their take on real-world practice. Survey data from European investigators suggests about half are already treating oligo-residual disease today. Watch the full discussion with @charlesrudin here ⬇️ lungsummit.org/metastatic-nsc…

First-in-human study of intravenous bispecific CTLA-4 × OX40 antibody (ATOR-1015) in advanced solid malignancies in @ESMO_Open. Most common TRAES: IRRs (n:14; 7 of G3), pyrexia, myalgia, rash. SD as best response in 39.3% of pts. esmoopen.com/article/S2059-…

Mutations in the tyrosine kinase domain of EGFR represent one of the most common druggable alterations in #NSCLC. This recent review provides a comprehensive clinical overview of the management of patients with EGFR-mutant NSCLC. acsjournals.onlinelibrary.wiley.com/doi/full/10.33… @OncoAlert @Alfdoc2

Impact of 1L amivantamab + lazertinib vs osimertinib on acquired resistance in EGFR mutant NSCLC @JTOonline. Ami/laz reduces MET amp (3.4% vs 13.1%) and acquired EGFR resistance mts (1.4% vs 7.6%). 2L PFS longer in ami/laz arm vs osi (8.4m vs 5.3m). jto.org/article/S1556-…

Molecular response is emerging as a key determinant in unresectable stage III NSCLC. At ILCS 2025, @AndrearicFili presented exploratory data from KN-799 showing that patients achieving ctDNA clearance by cycle 7 during IO maintenance rarely progress, while ctDNA-positive cases face poorer outcomes. Trials like ADAPT-C now aim to tailor consolidation based on MRD status. Watch the talk ⬇️ lungsummit.org/metastatic-nsc…

Are we finally ready to move beyond G12C and tackle G12D or even pan-RAS strategies in KRAS+ NSCLC? At our Year in Review roundtable, @MartinReck2 pointed to how quickly the field is moving, already pushing past second generation G12C inhibitors. Together with @peters_solange and @charlesrudin, he emphasized that KRAS is still a complex space, and the current challenge now is figuring out the right combinations for G12C. Watch the full talk here ⬇️ lungsummit.org/all-sessions/